Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

Figures & data

Table I.  Patients’ characteristics at start of first-line therapy.

Characteristics	No. of patients 112	%
Median age, Years (range)	60 (32–74)
Gender
Male	61	54
Female	51	46
0	54	48
I	43	38
II	15	14
Primary tumour site
Colon	68	61
Rectum	43	39
Missing	1
Prior adjuvant chemotherapy	16	14
Primary tumour resected	100	89
Organ involved
Liver	87	78
Lung	35	31
Lymph node	31	28
Peritoneum	13	12
Other soft tissue	16	14
Bone	8	7
Other	13	10
Liver metastases only	31	28
No of organs involved
1	42	38
2	43	38
≥3	27	24
Increased alkaline phosphatase (≥300 U/L)	64	58
Missing	2
Increased platelets (≥400×10^9/L)	34	30
Increased WBC count (≥10×10^9/L)	35	31

Table II.  Results from multiple logistic regression analyses assessing influence of baseline characteristics at start of first-line therapy on risk for not receiving second-line therapy.

	OR^a	p
WHO performance status II vs. 0–I	7.5	0.01
Alkaline phosphatase > 300 U/l vs.≤300 U/l	2.5	0.05
White blood cell count > 10×10^9/l vs.≤10×10^9/l	1.1	0.83
Platelets > 400×10^9/l vs.≤400×10^9/l	1.0	0.96
2 or more organs involved vs. one organ	1.1	0.77

^aOdds ratio. Serum alkaline phosphatase measured by IFCC (International Federation of Clinical Chemistry) method, normal range 90–285 U/l.

Table III.  Results from studies on effect of irinotecan-based second-line chemotherapy in metastatic colorectal cancer patients previously treated with oxaliplatin.

	Patient accrual	Line of treatment	n	% PR	% PR/SD	Median PFS (months)	Median Survival (months)
Tournigand et al. [6]	From 1-line study	2nd	69	4	55	2.5
Ulrich-Pur et al. [22]	Phase II	2nd	38	21	71	4.8	>9.5
Stickel et al. [23]	Retrospective	2nd + 3rd	26	27	62	5.8	10
Recchia et al. [24]	Phase II	2nd + 3rd	35	20	69	7.1	14
Mabro et al. [25]	Phase-II	2nd + 3rd	29	17	69	4.1	9.7
Mabro et al. [26]	Phase II	2nd + 3rd	65	23	60	4.7	10.5
Sørbye et al.	From 1-line study	2nd	59	7	59	4.1	9.5

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229–37

 PubMed Web of Science ®Google Scholar

Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12: 1269–72

 PubMed Web of Science ®Google Scholar

Stickel F, Jungert B, Brueckl V, Schirner I, Brueckl WM, Mannlein G, et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anti-Cancer Drugs 2003; 14: 745–9

 PubMed Web of Science ®Google Scholar

Recchia F, Saggio G, Nuzzo A, Lalli A, Di Lullo L, Cesta A, et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Can 2004; 91: 1442–6

 PubMed Web of Science ®Google Scholar

Mabro M, Louvet C, Andre T, Carola E, Gilles-Amar V, Artru P, et al. Bimonthly leucovorin, infusional 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003; 26: 254–8

 PubMed Web of Science ®Google Scholar

Mabro M, Artru P, Andre T, Flesch M, Maindrault-Goebel F, Landi B, et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006; 94: 1287–92

 PubMed Web of Science ®Google Scholar